TAK in the 13F filings
Takeda Pharmaceutical Co Ltd · CUSIP 874060205
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 14 Feb 2024
- latest of these filings; the earliest 13 Feb 2024
- Managers listing it
- 5
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 3 listed it in both
- Shares listed
- 26,201,337
- combined, among listed positions
- Reported value
- $374m
- combined, at the quarter end
Among the 93 comparable managers: 4 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TAK in Q4 2023
5 of 5 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Capital Research Global Investors | 14,297,805 | $204m | 0.05% | Added | +503,446 | 13 Feb 2024 (the filing on sec.gov) |
| Millennium Management LLC | 6,492,911 | $93m | under 0.1% | New | new | 14 Feb 2024 (the filing on sec.gov) |
| Renaissance Technologies LLC | 3,327,400 | $47m | 0.07% | Added | +96,500 | 13 Feb 2024 (the filing on sec.gov) |
| Arrowstreet Capital LP | 1,908,221 | $27m | under 0.1% | Trimmed | -565,689 | 14 Feb 2024 (the filing on sec.gov) |
| Hudson Bay Capital Management LP | 175,000 | $2.5m | under 0.1% | New | new | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Millennium Management LLCnew position · 6,492,911 shares now+6,492,911
- Capital Research Global Investorsexisting position · 14,297,805 shares now+503,446
- Hudson Bay Capital Management LPnew position · 175,000 shares now+175,000
- Renaissance Technologies LLCexisting position · 3,327,400 shares now+96,500
Reductions
- Arrowstreet Capital LPexisting position · 1,908,221 shares now-565,689
New positions and exits
New (2)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 3 | $83m | n.a. | n.a. |
| Q1 2019 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2019 | 6 | $721m | n.a. | n.a. |
| Q3 2019 | 9 | $718m | n.a. | n.a. |
| Q4 2019 | 6 | $645m | n.a. | n.a. |
| Q1 2020 | 4 | $362m | n.a. | n.a. |
| Q2 2020 | 4 | $395m | n.a. | n.a. |
| Q3 2020 | 4 | $423m | n.a. | n.a. |
| Q4 2020 | 5 | $549m | n.a. | n.a. |
| Q1 2021 | 4 | $699m | n.a. | n.a. |
| Q2 2021 | 4 | $476m | n.a. | n.a. |
| Q3 2021 | 4 | $410m | n.a. | n.a. |
| Q4 2021 | 2 | $111m | n.a. | n.a. |
| Q2 2022 | 3 | $69m | n.a. | n.a. |
| Q3 2022 | 3 | $68m | n.a. | n.a. |
| Q4 2022 | 5 | $208m | n.a. | n.a. |
| Q1 2023 | 5 | $349m | n.a. | n.a. |
| Q2 2023 | 5 | $353m | n.a. | n.a. |
| Q3 2023 | 4 | $311m | n.a. | n.a. |
| Q4 2023 | 5 | $374m | 4 | 1 |
| Q1 2024 | 3 | $228m | 0 | 2 |
| Q2 2024 | 4 | $243m | 3 | 1 |
| Q3 2024 | 3 | $236m | 2 | 1 |
| Q4 2024 | 3 | $271m | 1 | 2 |
| Q1 2025 | 3 | $256m | 3 | 0 |
| Q2 2025 | 2 | $257m | 2 | 0 |
| Q3 2025 | 2 | $253m | 2 | 0 |
| Q4 2025 | 4 | $355m | 11 | 8 |
| Q1 2026 | 3 | $467m | 13 | 7 |
| Q2 2026 | 3 | $410m | 13 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TAK and LLY →TAK and JNJ →TAK and VRTX →Choose a stock to compare with TAK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TAK, latest filings →Back to the 13F Explorer →